Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Venous Thrombosis

In brief

99mTc-rBitistatin is a radiolabeled polypeptide which is designed to stick to blood clots so that the blood clots can be detected by imaging. The purpose of this trial is to evaluate in patients the safety of 99mTc-rBitistatin and its ability to locate blood clots in the arms and legs.

Key facts

Study ID

NCT00808626

Run by

Temple University

People needed

0

Starts

2008-12-01

Expected to finish

2017-03-01

Last updated by the study team

2015-05-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• peripheral acute venous thrombosis diagnosed by vascular ultrasound
• is able to give informed consent
• is likely to complete the study

You may not qualify if…

• is pregnant
• is lactating
• has a history of prior severe allergic reactions (anaphylactic response)
• prior use of GP IIb/IIIa antagonist (e.g., abciximab, eptifibatide)
• has a platelet count <100,000 or history of thrombocytopenia
• has a history of stroke
• has a history of recent bleeding documented by decreasing hemoglobin (>1 gm) in last 7 days

Where it is running

• Temple University Hospital — Philadelphia, Pennsylvania, United States
• Temple University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.